Spots Global Cancer Trial Database for metastatic colorectal cancer
Every month we try and update this database with for metastatic colorectal cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pressure-enabled Delivery in Radioembolization (TriNav Study) | NCT05128032 | Liver Cancer Hepatocellular ... Metastatic Colo... | Standard microc... PEDD device | 18 Years - | Massachusetts General Hospital | |
| BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC | NCT03791398 | Metastatic Colo... | Dose level 1 ON... Dose level 2 ON... Dose level 3 ON... | 18 Years - | Brown University | |
| A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) | NCT04547166 | Metastatic Colo... | HLX10 HLX04、 | 18 Years - 75 Years | Shanghai Henlius Biotech | |
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment | NCT01134640 | Metastatic Colo... | - | Merck KGaA, Darmstadt, Germany | ||
| Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors | NCT03295084 | Metastatic Colo... | Irinotecan Capecitabine | 18 Years - | Herlev Hospital | |
| An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC) | NCT01039506 | Metastatic Colo... | CPT-11 based re... | - | Daiichi Sankyo | |
| Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) | NCT01281761 | Metastatic Colo... | cetuximab/irino... | 18 Years - | Samsung Medical Center | |
| Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer | NCT03340558 | Metastatic Colo... | Atezolizumab Cobimetinib | 18 Years - | Duke University | |
| Study of Ruxolitinib in Colorectal Cancer Patients | NCT02119676 | CRC (Colorectal... | Ruxolitinib Regorafenib Placebo | 18 Years - | Incyte Corporation | |
| Biomarker Directed Treatment in Metastatic Colorectal Cancer | NCT01703390 | Metastatic Colo... | FOLFIRI + Cetux... modifiedFOLFOX6... | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC | NCT03222089 | Metastatic Colo... | Irinotecan Oxaliplatin Levoleucovorin 5-FU GM-CSF IL-2 | 18 Years - 75 Years | Fujian Cancer Hospital | |
| 2nd-line Treatment of Metastatic Colorectal Cancer | NCT01532804 | Metastatic Colo... | bevacizumab, ox... Bevacizumab, ox... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer | NCT02063529 | Metastatic Colo... | FOLFOXIRI + Cet... FOLFOXIRI | 18 Years - 65 Years | Sun Yat-sen University | |
| Sym004 Versus TAS-102 in Patients With mCRC | NCT03717038 | Metastatic Colo... Colorectal Canc... Carcinoma | Sym004 TAS-102 | 18 Years - | Symphogen A/S | |
| Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer | NCT02497157 | Metastatic Colo... | Oxaliplatin (L-... Irinotecan hydr... Continuous intr... Levofolinate ca... Bevacizumab (Bm... | 20 Years - 70 Years | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | NCT06225622 | Metastatic Colo... | Irinotecan Lipo... Oxaliplatin 5-FU LV Bevacizumab Cetuximab | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer | NCT03892096 | Metastatic Non-... Metastatic Colo... Metastatic Brea... | Blood-based cel... | 18 Years - | Cadex Genomics | |
| Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol | NCT01196130 | Colorectal Canc... | Cancer Symptom ... Biomarker Testi... | 18 Years - | M.D. Anderson Cancer Center | |
| A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment | NCT06137170 | Metastatic Colo... | Regorafenib (St... | 18 Years - | Bayer | |
| Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | NCT05330429 | Metastatic Colo... | Magrolimab Bevacizumab Irinotecan Fluorouracil Leucovorin | 18 Years - | Gilead Sciences | |
| Centralized Tumour Board and Secondary Intervention Rate in mCRC | NCT04852250 | Metastatic Colo... RAS Mutation Multidisciplina... Secondary Inter... | Virtual central... | 18 Years - | Ludwig-Maximilians - University of Munich | |
| First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX | NCT00384176 | Colorectal Canc... | Cediranib Bevacizumab 5-fluorouracil ... Leucovorin (in ... Oxaliplatin (in... | 18 Years - 130 Years | AstraZeneca | |
| Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer | NCT03225937 | Metastatic Colo... | Trastuzumab, La... Pertuzumab, tra... | 18 Years - | Fondazione del Piemonte per l'Oncologia | |
| Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer | NCT01310478 | Colorectal Neop... | recombinant hum... | 17 Years - 70 Years | Fudan University | |
| Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer | NCT00233623 | Metastatic Colo... | Iressa (Gefitin... Irinotecan 5Fluorouracil Leucovorin | 18 Years - | AstraZeneca | |
| A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI | NCT04247256 | Metastatic Colo... | FOLFIRI Protoco... SCO-101 | 18 Years - | Scandion Oncology A/S | |
| lead-in FOLICOLOR Trial: Following Therapy Response Through Liquid Biopsy in Metastatic Colorectal Cancer Patients | NCT04735900 | Metastatic Colo... | Liquid biopsy s... | 18 Years - | University Hospital, Antwerp | |
| A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) | NCT00851136 | Metastatic Colo... | bevacizumab FOLFOX PRO95780 | 18 Years - | Genentech, Inc. | |
| Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer | NCT04561336 | Metastatic Colo... RAS Wild Type | Avelumab Cetuximab | 18 Years - | University of Campania "Luigi Vanvitelli" | |
| Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC | NCT05004831 | Metastatic Colo... | fruquintinib pl... | 18 Years - 75 Years | Sun Yat-sen University | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | NCT04140526 | Non Small Cell ... Advanced Solid ... Metastatic Mela... Metastatic Head... Metastatic Rena... Metastatic Colo... Sarcomas Metastatic Pros... Ovarian Cancer Small Cell Lung... Metastatic Brea... Pancreas Cancer Gastric Cancer Esophageal Canc... Gastroesophagea... Cervical Cancer Adenoid Cystic ... Salivary Gland ... Urothelial Carc... | ONC-392 Pembrolizumab Docetaxel | 18 Years - | OncoC4, Inc. | |
| Clinical Evaluation of PET-CT for Staging of Colorectal Lung Metastases | NCT02942901 | Metastatic Colo... | PET-CT | 18 Years - | Lung Clinic Heckeshorn | |
| Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). | NCT02296203 | Metastatic Colo... | cetuximab irinotecan | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells | NCT01286883 | Colorectal Canc... | 18 Years - | Milton S. Hershey Medical Center | ||
| FOLFIRI and Sunitinib in Metastatic Colorectal Cancer | NCT00806663 | Metastatic Colo... Liver Metastase... | sunitinib added... | 18 Years - 80 Years | Central European Society for Anticancer Drug Research | |
| Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer | NCT01051167 | Metastatic Colo... | Cetuximab | 18 Years - | Universität Duisburg-Essen | |
| [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib | NCT02175095 | Colorectal Canc... | Regorafenib | 20 Years - | Asan Medical Center | |
| ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | NCT01075048 | Metastatic Colo... | Tivantinib Placebo Cetuximab Irinotecan | 18 Years - | Daiichi Sankyo | |
| Nitazoxanide in Patients With Metastatic Colorectal Cancer | NCT06049901 | Metastatic Colo... | Nitazoxanide | 18 Years - 65 Years | Tanta University | |
| Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer | NCT03532711 | Metastatic Colo... Chemotherapy Ef... Biomarker | fluorouracil | 18 Years - 80 Years | Fudan University | |
| Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment | NCT02624726 | Metastatic Colo... | 5 Fluorouracil Leucovorin Irinotecan Aflibercept | 18 Years - | Hellenic Oncology Research Group | |
| Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer | NCT03542877 | Colorectal Canc... | Oral Tablet: Ca... | 18 Years - 99 Years | University of Colorado, Denver | |
| Sym004 Versus Futuximab or Modotuximab in Patients With mCRC | NCT03549338 | Metastatic Colo... Colorectal Canc... Carcinoma | Sym004 Futuximab Modotuximab | 18 Years - | Symphogen A/S | |
| Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours | NCT01161316 | Metastatic Colo... | mFOLFOX-6 + cet... 8 cycles of mFO... | 18 Years - 70 Years | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras | NCT01651013 | Metastatic Colo... | 18 Years - | National Cancer Institute, Naples | ||
| Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer | NCT01051167 | Metastatic Colo... | Cetuximab | 18 Years - | Universität Duisburg-Essen | |
| Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer | NCT03892096 | Metastatic Non-... Metastatic Colo... Metastatic Brea... | Blood-based cel... | 18 Years - | Cadex Genomics | |
| Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer | NCT02181556 | Metastatic Colo... | FOLFIRI Protoco... Aflibercept Inj... | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis | NCT02345746 | Metastatic Colo... | Oxaliplatin Folinic Acid 5-Fluorouracil | 18 Years - | Western Regional Medical Center | |
| A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer | NCT01767857 | Metastatic Colo... | Xilonix Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer | NCT04008511 | Metastatic Colo... | Regorafenib Regorafenib Capecitabine Oxaliplatin | 18 Years - 75 Years | China Medical University, China | |
| Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC | NCT03222089 | Metastatic Colo... | Irinotecan Oxaliplatin Levoleucovorin 5-FU GM-CSF IL-2 | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer | NCT00120172 | Colorectal Canc... Neoplasm Metast... | oxaliplatin, ca... | 65 Years - | Geriatric Oncology Consortium | |
| Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells | NCT01640405 | Metastatic Colo... | modified FOLFOX... FOLFOXIRI + Bev... | 18 Years - 70 Years | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| Mix Vaccine for Metastatic Colorectal Cancer | NCT03357276 | Metastatic Colo... Reaction - Mixe... | Mix vaccine | 40 Years - 70 Years | Fuda Cancer Hospital, Guangzhou | |
| Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP) | NCT02511756 | Metastatic Colo... | Computed tomogr... | 18 Years - | University of Zurich | |
| Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer | NCT01661972 | Metastatic Colo... | Capecitabine an... | 18 Years - | Duke University | |
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | NCT05198934 | Colorectal Canc... | Sotorasib Panitumumab Trifluridine an... Regorafenib | 18 Years - 100 Years | Amgen | |
| Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib | NCT03386825 | Colorectal Neop... | Regorafenib (St... | 18 Years - | Bayer | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients | NCT01732783 | Wild-type RAS M... | Panitumumab + C... | 18 Years - | Amgen | |
| Phase II Efficacy Study of AZD6244 in Colorectal Cancer | NCT00514761 | Metastatic Colo... | AZD6244 Capecitabine | 18 Years - | AstraZeneca | |
| Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer | NCT00286130 | Metastatic Colo... | Cetuximab, Oxal... FOLFOX 6 FOLFIRI | 18 Years - | Central European Cooperative Oncology Group | |
| A Study to Evaluate Safety and Efficacy of BEY1107 in Combination With Capecitabine in Patients With Metastatic Colorectal Cancer | NCT05093907 | Metastatic Colo... | BEY1107 Capecitabine | 19 Years - | BeyondBio Inc. | |
| The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) | NCT04948034 | Metastatic Colo... | Stereotactic Ab... Fruquintinib Tislelizumab | 18 Years - | Fudan University | |
| Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer | NCT02575378 | Metastatic Colo... | Metronimic chem... Metronimic chem... | 18 Years - 75 Years | Ruijin Hospital | |
| A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer | NCT03356158 | Metastatic Colo... | CPGJ602 Cetuximab | 18 Years - 70 Years | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | |
| EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options | NCT03602885 | Metastatic Panc... Unresectable Pa... Metastatic Colo... | Usual chemother... Chemotherapy ed... | 21 Years - | Dana-Farber Cancer Institute | |
| Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib | NCT03386825 | Colorectal Neop... | Regorafenib (St... | 18 Years - | Bayer | |
| LifePearl-Iri Pharmacokinetic Study | NCT02547480 | Metastatic Colo... mCRC | TACE with irino... | 18 Years - | Terumo Europe N.V. | |
| PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases | NCT01410760 | Metastatic Colo... | Perfusion CT sc... | 18 Years - | University of Oxford | |
| Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients | NCT01523431 | Metastatic Colo... | Irinotecan Inje... 5-fluorouracil Leucovorin | 18 Years - | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies | NCT03274882 | Metastatic Colo... | S95005 | 18 Years - | Servier | |
| Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer | NCT00378066 | Metastatic Colo... | Bevacizumab | 18 Years - 70 Years | Asan Medical Center | |
| Safety of Effivia®, a Bevacizumab Biosimilar | NCT06313268 | Metastatic Colo... Metastatic Cerv... Non Squamous No... | Bevacizumab Bio... | 18 Years - | Laboratorios Liomont | |
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation | NCT05198934 | Colorectal Canc... | Sotorasib Panitumumab Trifluridine an... Regorafenib | 18 Years - 100 Years | Amgen | |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | NCT06228326 | Lung Cancer, No... Lung Cancer Met... Solid Tumor, Ad... Advanced Cancer Lung Cancer, Sm... Metastatic Colo... Metastatic Rena... Metastatic Hepa... Metastatic Sarc... Metastatic Oste... | KB707 | 18 Years - | Krystal Biotech, Inc. | |
| Regorafenib in Metastatic Colorectal Cancer | NCT02466009 | Metastatic Colo... | Regorafenib | 70 Years - | University of Rochester | |
| Erbitux MEtastatic Colorectal Cancer Strategy Study | NCT02484833 | Antineoplastic ... | Cetuximab FOLFIRI | 18 Years - | Catholic University of the Sacred Heart | |
| Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer | NCT05462613 | Metastatic Colo... | quality of life... Blood sample Regorafenib Metronomic chem... Aspirin Bevacizumab FOLFIRI or FOLF... | 18 Years - | Centre Hospitalier Universitaire de Besancon |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
